Medexus Pharmaceuticals (TSE:MDP) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Medexus Pharmaceuticals (TSE:MDP) had its price target lifted by Stifel Nicolaus from C$4.50 to C$6.00 in a research note issued to investors on Thursday,BayStreet.CA reports.

A number of other analysts have also weighed in on the company. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a research note on Wednesday, January 8th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Finally, Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Two analysts have rated the stock with a buy rating and five have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Strong Buy” and an average price target of C$6.13.

Medexus Pharmaceuticals Price Performance

TSE:MDP opened at C$3.85 on Thursday. The company has a market capitalization of C$94.44 million, a price-to-earnings ratio of 77.00 and a beta of 1.96. The business has a 50 day moving average of C$3.44 and a 200 day moving average of C$2.78. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.